{"transactions":[{"id":1085667,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":77431,"kind":"person","name":"Kling Douglas F","position":1,"cik":"0001699022","reported_name":"Kling Douglas F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Option (right to buy)","published_at":"2025-07-17T21:19:01.000Z","date":"2025-07-16","kind":"exercise","planned":true,"acquired":false,"shares":51043,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option was granted on January 1, 2023. 25% of the shares underlying the option vested on the one-year anniversary of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date."}],"balance_after":162702,"derivative":{"exercise_price":10.9,"expiration_date":"2033-01-01","underlying":"Ordinary Shares","underlying_shares":51043},"source":{"system":"sec-edgar","filing":"0000950170-25-096665","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000095017025096665/ownership.xml","form_type":"4"}},{"id":1085666,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":77431,"kind":"person","name":"Kling Douglas F","position":1,"cik":"0001699022","reported_name":"Kling Douglas F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Option (right to buy)","published_at":"2025-07-17T21:19:01.000Z","date":"2025-07-15","kind":"exercise","planned":true,"acquired":false,"shares":47569,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option was granted on January 1, 2023. 25% of the shares underlying the option vested on the one-year anniversary of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date."}],"balance_after":213745,"derivative":{"exercise_price":10.9,"expiration_date":"2033-01-01","underlying":"Ordinary Shares","underlying_shares":47569},"source":{"system":"sec-edgar","filing":"0000950170-25-096665","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000095017025096665/ownership.xml","form_type":"4"}},{"id":1085665,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":77431,"kind":"person","name":"Kling Douglas F","position":1,"cik":"0001699022","reported_name":"Kling Douglas F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2025-07-17T21:19:01.000Z","date":"2025-07-16","kind":"sale","planned":true,"acquired":false,"shares":51043,"price":21.1,"value":1077007.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.88 per share to $21.56 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction."}],"balance_after":44000,"source":{"system":"sec-edgar","filing":"0000950170-25-096665","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000095017025096665/ownership.xml","form_type":"4"}},{"id":1085664,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":77431,"kind":"person","name":"Kling Douglas F","position":1,"cik":"0001699022","reported_name":"Kling Douglas F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2025-07-17T21:19:01.000Z","date":"2025-07-16","kind":"exercise","planned":true,"acquired":true,"shares":51043,"price":10.9,"value":556368.7,"ownership":{"direct":true},"balance_after":95043,"source":{"system":"sec-edgar","filing":"0000950170-25-096665","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000095017025096665/ownership.xml","form_type":"4"}},{"id":1085663,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":77431,"kind":"person","name":"Kling Douglas F","position":1,"cik":"0001699022","reported_name":"Kling Douglas F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2025-07-17T21:19:01.000Z","date":"2025-07-15","kind":"sale","planned":true,"acquired":false,"shares":3544,"price":22.12,"value":78393.28,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.02 per share to $22.22 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction."}],"balance_after":44000,"source":{"system":"sec-edgar","filing":"0000950170-25-096665","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000095017025096665/ownership.xml","form_type":"4"}},{"id":1085662,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":77431,"kind":"person","name":"Kling Douglas F","position":1,"cik":"0001699022","reported_name":"Kling Douglas F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2025-07-17T21:19:01.000Z","date":"2025-07-15","kind":"sale","planned":true,"acquired":false,"shares":44025,"price":21.38,"value":941254.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.02 per share to $22.01 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction."}],"balance_after":47544,"source":{"system":"sec-edgar","filing":"0000950170-25-096665","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000095017025096665/ownership.xml","form_type":"4"}},{"id":1085661,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":77431,"kind":"person","name":"Kling Douglas F","position":1,"cik":"0001699022","reported_name":"Kling Douglas F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2025-07-17T21:19:01.000Z","date":"2025-07-15","kind":"exercise","planned":true,"acquired":true,"shares":47569,"price":10.9,"value":518502.1,"ownership":{"direct":true},"balance_after":91569,"source":{"system":"sec-edgar","filing":"0000950170-25-096665","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000095017025096665/ownership.xml","form_type":"4"}},{"id":1106561,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":77431,"kind":"person","name":"Kling Douglas F","position":1,"cik":"0001699022","reported_name":"Kling Douglas F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Option (right to buy)","published_at":"2025-06-18T20:50:44.000Z","date":"2025-06-16","kind":"exercise","planned":true,"acquired":false,"shares":21899,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option was granted on January 1, 2023. 25% of the shares underlying the option vested on the one-year anniversary of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date."}],"balance_after":261314,"derivative":{"exercise_price":10.9,"expiration_date":"2033-01-01","underlying":"Ordinary Shares","underlying_shares":21899},"source":{"system":"sec-edgar","filing":"0000950170-25-087937","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000095017025087937/ownership.xml","form_type":"4"}},{"id":1106560,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":77431,"kind":"person","name":"Kling Douglas F","position":1,"cik":"0001699022","reported_name":"Kling Douglas F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Option (right to buy)","published_at":"2025-06-18T20:50:44.000Z","date":"2025-06-16","kind":"exercise","planned":true,"acquired":false,"shares":78101,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option was granted on November 22, 2022. The shares underlying the option vest in equal monthly installments over four years, with the first 1/48th of such shares vesting on December 22, 2022 and the remaining installments vesting on each one-month anniversary of the grant date, subject to the Reporting Person's continued service through each such date."}],"balance_after":372829,"derivative":{"exercise_price":10,"expiration_date":"2032-11-22","underlying":"Ordinary Shares","underlying_shares":78101},"source":{"system":"sec-edgar","filing":"0000950170-25-087937","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000095017025087937/ownership.xml","form_type":"4"}},{"id":1106559,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":77431,"kind":"person","name":"Kling Douglas F","position":1,"cik":"0001699022","reported_name":"Kling Douglas F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2025-06-18T20:50:44.000Z","date":"2025-06-16","kind":"sale","planned":true,"acquired":false,"shares":18109,"price":19.75,"value":357652.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.60 per share to $20.21 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction."}],"balance_after":44000,"source":{"system":"sec-edgar","filing":"0000950170-25-087937","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000095017025087937/ownership.xml","form_type":"4"}},{"id":1106558,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":77431,"kind":"person","name":"Kling Douglas F","position":1,"cik":"0001699022","reported_name":"Kling Douglas F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2025-06-18T20:50:44.000Z","date":"2025-06-16","kind":"sale","planned":true,"acquired":false,"shares":81891,"price":19.19,"value":1571488.29,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.60 per share to $19.59 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction."}],"balance_after":62109,"source":{"system":"sec-edgar","filing":"0000950170-25-087937","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000095017025087937/ownership.xml","form_type":"4"}},{"id":1106557,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":77431,"kind":"person","name":"Kling Douglas F","position":1,"cik":"0001699022","reported_name":"Kling Douglas F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2025-06-18T20:50:44.000Z","date":"2025-06-16","kind":"exercise","planned":true,"acquired":true,"shares":21899,"price":10.9,"value":238699.1,"ownership":{"direct":true},"balance_after":144000,"source":{"system":"sec-edgar","filing":"0000950170-25-087937","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000095017025087937/ownership.xml","form_type":"4"}},{"id":1106556,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":77431,"kind":"person","name":"Kling Douglas F","position":1,"cik":"0001699022","reported_name":"Kling Douglas F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2025-06-18T20:50:44.000Z","date":"2025-06-16","kind":"exercise","planned":true,"acquired":true,"shares":78101,"price":10,"value":781010.0,"ownership":{"direct":true},"balance_after":122101,"source":{"system":"sec-edgar","filing":"0000950170-25-087937","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000095017025087937/ownership.xml","form_type":"4"}},{"id":1143134,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":77431,"kind":"person","name":"Kling Douglas F","position":1,"cik":"0001699022","reported_name":"Kling Douglas F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Option (right to buy)","published_at":"2025-05-19T20:44:25.000Z","date":"2025-05-15","kind":"exercise","planned":true,"acquired":false,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option was granted on November 22, 2022. The shares underlying the option vest in equal monthly installments over four years, with the first 1/48th of such shares vesting on December 22, 2022 and the remaining installments vesting on each one-month anniversary of the grant date, subject to the Reporting Person's continued service through each such date."}],"balance_after":450930,"derivative":{"exercise_price":10,"expiration_date":"2032-11-22","underlying":"Ordinary Shares","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000950170-25-074463","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000095017025074463/ownership.xml","form_type":"4"}},{"id":1143133,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":77431,"kind":"person","name":"Kling Douglas F","position":1,"cik":"0001699022","reported_name":"Kling Douglas F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2025-05-19T20:44:25.000Z","date":"2025-05-15","kind":"sale","planned":true,"acquired":false,"shares":100000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"These shares were sold in multiple transactions at prices ranging from $18.38 per share to $18.89 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction."}],"balance_after":44000,"source":{"system":"sec-edgar","filing":"0000950170-25-074463","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000095017025074463/ownership.xml","form_type":"4"}},{"id":1143132,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":77431,"kind":"person","name":"Kling Douglas F","position":1,"cik":"0001699022","reported_name":"Kling Douglas F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2025-05-19T20:44:25.000Z","date":"2025-05-15","kind":"exercise","planned":true,"acquired":true,"shares":100000,"price":10,"value":1000000.0,"ownership":{"direct":true},"balance_after":144000,"source":{"system":"sec-edgar","filing":"0000950170-25-074463","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000095017025074463/ownership.xml","form_type":"4"}},{"id":1169934,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":77431,"kind":"person","name":"Kling Douglas F","position":1,"cik":"0001699022","reported_name":"Kling Douglas F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Option (right to buy)","published_at":"2025-04-17T21:41:07.000Z","date":"2025-04-15","kind":"exercise","planned":true,"acquired":false,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option was granted on November 22, 2022. The shares underlying the option vest in equal monthly installments over four years, with the first 1/48th of such shares vesting on December 22, 2022 and the remaining installments vesting on each one-month anniversary of the grant date, subject to the Reporting Person's continued service through each such date."}],"balance_after":550930,"derivative":{"exercise_price":10,"expiration_date":"2032-11-22","underlying":"Ordinary Shares","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000950170-25-055612","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000095017025055612/ownership.xml","form_type":"4"}},{"id":1169933,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":77431,"kind":"person","name":"Kling Douglas F","position":1,"cik":"0001699022","reported_name":"Kling Douglas F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2025-04-17T21:41:07.000Z","date":"2025-04-15","kind":"sale","planned":true,"acquired":false,"shares":910,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"These shares were sold in multiple transactions at prices ranging from $16.70 per share to $16.88 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction."}],"balance_after":44000,"source":{"system":"sec-edgar","filing":"0000950170-25-055612","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000095017025055612/ownership.xml","form_type":"4"}},{"id":1169932,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":77431,"kind":"person","name":"Kling Douglas F","position":1,"cik":"0001699022","reported_name":"Kling Douglas F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2025-04-17T21:41:07.000Z","date":"2025-04-15","kind":"sale","planned":true,"acquired":false,"shares":99090,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"These shares were sold in multiple transactions at prices ranging from $15.70 per share to $16.65 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction."}],"balance_after":44910,"source":{"system":"sec-edgar","filing":"0000950170-25-055612","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000095017025055612/ownership.xml","form_type":"4"}},{"id":1169931,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":77431,"kind":"person","name":"Kling Douglas F","position":1,"cik":"0001699022","reported_name":"Kling Douglas F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2025-04-17T21:41:07.000Z","date":"2025-04-15","kind":"exercise","planned":true,"acquired":true,"shares":100000,"price":10,"value":1000000.0,"ownership":{"direct":true},"balance_after":144000,"source":{"system":"sec-edgar","filing":"0000950170-25-055612","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000095017025055612/ownership.xml","form_type":"4"}},{"id":1188937,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":77431,"kind":"person","name":"Kling Douglas F","position":1,"cik":"0001699022","reported_name":"Kling Douglas F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Restricted Stock Unit","published_at":"2025-03-28T21:18:13.000Z","date":"2025-03-26","kind":"exercise","planned":false,"acquired":false,"shares":16539,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each RSU represents a contingent right to receive one ordinary share."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The RSUs were granted on March 26, 2025 as earnout RSUs pursuant to the business combination agreement, dated as of July 25, 2022, by and among the issuer, Frazier Lifesicences Acquisition Corporation, NewAmsterdam Pharma Holding B.V., and NewAmsterdam Pharma Investment Corporation (the \"BCA\"). The BCA provided that certain optionholders would receive RSUs of the issuer, determined in accordance with a formula set forth in the BCA and for no additional consideration, if a certain clinical development milestone was achieved within five years of the Closing Date. The Reporting Person's right to receive the earnout RSUs became fixed and irrevocable on the Closing Date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Upon grant, all of the RSUs were fully-vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Upon grant, all of the RSUs were fully-vested."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":16539},"source":{"system":"sec-edgar","filing":"0000950170-25-046943","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000095017025046943/ownership.xml","form_type":"4"}},{"id":1188936,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":77431,"kind":"person","name":"Kling Douglas F","position":1,"cik":"0001699022","reported_name":"Kling Douglas F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Restricted Stock Unit","published_at":"2025-03-28T21:18:13.000Z","date":"2025-03-26","kind":"grant","planned":false,"acquired":true,"shares":16539,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each RSU represents a contingent right to receive one ordinary share."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The RSUs were granted on March 26, 2025 as earnout RSUs pursuant to the business combination agreement, dated as of July 25, 2022, by and among the issuer, Frazier Lifesicences Acquisition Corporation, NewAmsterdam Pharma Holding B.V., and NewAmsterdam Pharma Investment Corporation (the \"BCA\"). The BCA provided that certain optionholders would receive RSUs of the issuer, determined in accordance with a formula set forth in the BCA and for no additional consideration, if a certain clinical development milestone was achieved within five years of the Closing Date. The Reporting Person's right to receive the earnout RSUs became fixed and irrevocable on the Closing Date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Upon grant, all of the RSUs were fully-vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Upon grant, all of the RSUs were fully-vested."}],"balance_after":16539,"derivative":{"underlying":"Ordinary Shares","underlying_shares":16539},"source":{"system":"sec-edgar","filing":"0000950170-25-046943","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000095017025046943/ownership.xml","form_type":"4"}},{"id":1188935,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":77431,"kind":"person","name":"Kling Douglas F","position":1,"cik":"0001699022","reported_name":"Kling Douglas F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2025-03-28T21:18:13.000Z","date":"2025-03-26","kind":"sale","planned":false,"acquired":false,"shares":16539,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares were sold in multiple transactions at a price ranging from $22.75 to $23.20 per share. A portion of the ordinary shares were sold to satisfy tax withholding obligations arising upon the vesting of the restricted stock units (\"RSUs\"). The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities Exchange Comission, upon request, full information regarding the number of shares sold in each transaction."}],"balance_after":44000,"source":{"system":"sec-edgar","filing":"0000950170-25-046943","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000095017025046943/ownership.xml","form_type":"4"}},{"id":1188934,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":77431,"kind":"person","name":"Kling Douglas F","position":1,"cik":"0001699022","reported_name":"Kling Douglas F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2025-03-28T21:18:13.000Z","date":"2025-03-26","kind":"exercise","planned":false,"acquired":true,"shares":16539,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":60539,"source":{"system":"sec-edgar","filing":"0000950170-25-046943","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000095017025046943/ownership.xml","form_type":"4"}},{"id":1197339,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":77431,"kind":"person","name":"Kling Douglas F","position":1,"cik":"0001699022","reported_name":"Kling Douglas F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Option (right to buy)","published_at":"2025-03-19T21:29:57.000Z","date":"2025-03-17","kind":"exercise","planned":true,"acquired":false,"shares":11888,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option was granted on November 22, 2022. The shares underlying the option vest in equal monthly installments over four years, with the first 1/48th of such shares vesting on December 22, 2022 and the remaining installments vesting on each one-month anniversary of the grant date, subject to the Reporting Person's continued service through each such date."}],"balance_after":650930,"derivative":{"exercise_price":10,"expiration_date":"2032-11-22","underlying":"Ordinary Shares","underlying_shares":11888},"source":{"system":"sec-edgar","filing":"0000950170-25-042176","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000095017025042176/ownership.xml","form_type":"4"}},{"id":1197338,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":77431,"kind":"person","name":"Kling Douglas F","position":1,"cik":"0001699022","reported_name":"Kling Douglas F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Option (right to buy)","published_at":"2025-03-19T21:29:57.000Z","date":"2025-03-17","kind":"exercise","planned":true,"acquired":false,"shares":88112,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The exercise price of the option is 1.16392 euros."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option was granted on November 22, 2022 to replace an option originally granted on July 6, 2021, which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 121,754 of the shares underlying the option immediately vested on the grant date. 25% of the remaining shares underlying the option vested on March 31, 2022, the one-year anniversary of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date."}],"balance_after":47251,"derivative":{"expiration_date":"2031-07-06","underlying":"Ordinary Shares","underlying_shares":88112},"source":{"system":"sec-edgar","filing":"0000950170-25-042176","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000095017025042176/ownership.xml","form_type":"4"}},{"id":1197337,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":77431,"kind":"person","name":"Kling Douglas F","position":1,"cik":"0001699022","reported_name":"Kling Douglas F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2025-03-19T21:29:57.000Z","date":"2025-03-17","kind":"sale","planned":true,"acquired":false,"shares":100000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"These shares were sold in multiple transactions at prices ranging from $23.16 per share to $23.66 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction."}],"balance_after":44000,"source":{"system":"sec-edgar","filing":"0000950170-25-042176","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000095017025042176/ownership.xml","form_type":"4"}},{"id":1197336,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":77431,"kind":"person","name":"Kling Douglas F","position":1,"cik":"0001699022","reported_name":"Kling Douglas F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2025-03-19T21:29:57.000Z","date":"2025-03-17","kind":"exercise","planned":true,"acquired":true,"shares":11888,"price":10,"value":118880.0,"ownership":{"direct":true},"balance_after":144000,"source":{"system":"sec-edgar","filing":"0000950170-25-042176","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000095017025042176/ownership.xml","form_type":"4"}},{"id":1197335,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":77431,"kind":"person","name":"Kling Douglas F","position":1,"cik":"0001699022","reported_name":"Kling Douglas F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2025-03-19T21:29:57.000Z","date":"2025-03-17","kind":"exercise","planned":true,"acquired":true,"shares":88112,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The exercise price of the option is 1.16392 euros."}],"balance_after":132112,"source":{"system":"sec-edgar","filing":"0000950170-25-042176","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000095017025042176/ownership.xml","form_type":"4"}},{"id":1256190,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":77431,"kind":"person","name":"Kling Douglas F","position":1,"cik":"0001699022","reported_name":"Kling Douglas F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Option (right to buy)","published_at":"2025-02-20T22:24:36.000Z","date":"2025-02-19","kind":"exercise","planned":true,"acquired":false,"shares":9218,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"This transaction was effected pursuant to a trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option was granted on November 22, 2022 to replace an option originally granted on July 6, 2021, which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 121,754 of the shares underlying the option immediately vested on the grant date. 25% of the remaining shares underlying the option vested on March 31, 2022, the one-year anniversary of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date."}],"balance_after":126145,"derivative":{"expiration_date":"2031-07-06","underlying":"Ordinary Shares","underlying_shares":9218},"source":{"system":"sec-edgar","filing":"0000950170-25-024322","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000095017025024322/ownership.xml","form_type":"4"}},{"id":1256189,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":77431,"kind":"person","name":"Kling Douglas F","position":1,"cik":"0001699022","reported_name":"Kling Douglas F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Option (right to buy)","published_at":"2025-02-20T22:24:36.000Z","date":"2025-02-18","kind":"exercise","planned":true,"acquired":false,"shares":90782,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The exercise price of the option is 1.16392 euros."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option was granted on November 22, 2022 to replace an option originally granted on July 6, 2021, which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 121,754 of the shares underlying the option immediately vested on the grant date. 25% of the remaining shares underlying the option vested on March 31, 2022, the one-year anniversary of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date."}],"balance_after":135363,"derivative":{"expiration_date":"2031-07-06","underlying":"Ordinary Shares","underlying_shares":90782},"source":{"system":"sec-edgar","filing":"0000950170-25-024322","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000095017025024322/ownership.xml","form_type":"4"}},{"id":1256188,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":77431,"kind":"person","name":"Kling Douglas F","position":1,"cik":"0001699022","reported_name":"Kling Douglas F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2025-02-20T22:24:36.000Z","date":"2025-02-19","kind":"sale","planned":true,"acquired":false,"shares":9218,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"These shares were sold in multiple transactions at prices ranging from $19.23 per share to $20.18 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction."}],"balance_after":44000,"source":{"system":"sec-edgar","filing":"0000950170-25-024322","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000095017025024322/ownership.xml","form_type":"4"}},{"id":1256187,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":77431,"kind":"person","name":"Kling Douglas F","position":1,"cik":"0001699022","reported_name":"Kling Douglas F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2025-02-20T22:24:36.000Z","date":"2025-02-19","kind":"exercise","planned":true,"acquired":true,"shares":9218,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The exercise price of the option is 1.16392 euros."}],"balance_after":53218,"source":{"system":"sec-edgar","filing":"0000950170-25-024322","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000095017025024322/ownership.xml","form_type":"4"}},{"id":1256186,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":77431,"kind":"person","name":"Kling Douglas F","position":1,"cik":"0001699022","reported_name":"Kling Douglas F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2025-02-20T22:24:36.000Z","date":"2025-02-18","kind":"sale","planned":true,"acquired":false,"shares":90782,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"These shares were sold in multiple transactions at prices ranging from $19.54 per share to $20.38 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction."}],"balance_after":44000,"source":{"system":"sec-edgar","filing":"0000950170-25-024322","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000095017025024322/ownership.xml","form_type":"4"}},{"id":1256185,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":77431,"kind":"person","name":"Kling Douglas F","position":1,"cik":"0001699022","reported_name":"Kling Douglas F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2025-02-20T22:24:36.000Z","date":"2025-02-18","kind":"exercise","planned":true,"acquired":true,"shares":90782,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The exercise price of the option is 1.16392 euros."}],"balance_after":134782,"source":{"system":"sec-edgar","filing":"0000950170-25-024322","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000095017025024322/ownership.xml","form_type":"4"}},{"id":1289702,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":77431,"kind":"person","name":"Kling Douglas F","position":1,"cik":"0001699022","reported_name":"Kling Douglas F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Option (right to buy)","published_at":"2025-01-31T22:00:12.000Z","date":"2025-01-30","kind":"exercise","planned":true,"acquired":false,"shares":13578,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The exercise price of the option is 1.16392 euros."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The option was granted on November 22, 2022 to replace an option originally granted on July 6, 2021, which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 121,754 of the shares underlying the option immediately vested on the grant date. 25% of the remaining shares underlying the option vested on March 31, 2022, the one-year anniversary of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date."}],"balance_after":226145,"derivative":{"expiration_date":"2031-07-06","underlying":"Ordinary Shares","underlying_shares":13578},"source":{"system":"sec-edgar","filing":"0000950170-25-011854","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000095017025011854/ownership.xml","form_type":"4"}},{"id":1289701,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":77431,"kind":"person","name":"Kling Douglas F","position":1,"cik":"0001699022","reported_name":"Kling Douglas F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Option (right to buy)","published_at":"2025-01-31T22:00:12.000Z","date":"2025-01-29","kind":"exercise","planned":true,"acquired":false,"shares":56863,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The exercise price of the option is 1.16392 euros."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The option was granted on November 22, 2022 to replace an option originally granted on July 6, 2021, which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 121,754 of the shares underlying the option immediately vested on the grant date. 25% of the remaining shares underlying the option vested on March 31, 2022, the one-year anniversary of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date."}],"balance_after":239723,"derivative":{"expiration_date":"2031-07-06","underlying":"Ordinary Shares","underlying_shares":56863},"source":{"system":"sec-edgar","filing":"0000950170-25-011854","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000095017025011854/ownership.xml","form_type":"4"}},{"id":1289700,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":77431,"kind":"person","name":"Kling Douglas F","position":1,"cik":"0001699022","reported_name":"Kling Douglas F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2025-01-31T22:00:12.000Z","date":"2025-01-30","kind":"sale","planned":true,"acquired":false,"shares":8914,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"These shares were sold in multiple transactions at prices ranging from $21.33 per share to $21.93 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction."}],"balance_after":44000,"source":{"system":"sec-edgar","filing":"0000950170-25-011854","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000095017025011854/ownership.xml","form_type":"4"}},{"id":1289699,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":77431,"kind":"person","name":"Kling Douglas F","position":1,"cik":"0001699022","reported_name":"Kling Douglas F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2025-01-31T22:00:12.000Z","date":"2025-01-30","kind":"sale","planned":true,"acquired":false,"shares":4664,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"These shares were sold in multiple transactions at prices ranging from $20.33 per share to $21.32 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction."}],"balance_after":52914,"source":{"system":"sec-edgar","filing":"0000950170-25-011854","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000095017025011854/ownership.xml","form_type":"4"}},{"id":1289698,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":77431,"kind":"person","name":"Kling Douglas F","position":1,"cik":"0001699022","reported_name":"Kling Douglas F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2025-01-31T22:00:12.000Z","date":"2025-01-30","kind":"exercise","planned":true,"acquired":true,"shares":13578,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The exercise price of the option is 1.16392 euros."}],"balance_after":57578,"source":{"system":"sec-edgar","filing":"0000950170-25-011854","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000095017025011854/ownership.xml","form_type":"4"}},{"id":1289697,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":77431,"kind":"person","name":"Kling Douglas F","position":1,"cik":"0001699022","reported_name":"Kling Douglas F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2025-01-31T22:00:12.000Z","date":"2025-01-29","kind":"sale","planned":true,"acquired":false,"shares":56863,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"These shares were sold in multiple transactions at prices ranging from $20.60 per share to $21.50 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction."}],"balance_after":44000,"source":{"system":"sec-edgar","filing":"0000950170-25-011854","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000095017025011854/ownership.xml","form_type":"4"}},{"id":1289696,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":77431,"kind":"person","name":"Kling Douglas F","position":1,"cik":"0001699022","reported_name":"Kling Douglas F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2025-01-31T22:00:12.000Z","date":"2025-01-29","kind":"exercise","planned":true,"acquired":true,"shares":56863,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The exercise price of the option is 1.16392 euros."}],"balance_after":100863,"source":{"system":"sec-edgar","filing":"0000950170-25-011854","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000095017025011854/ownership.xml","form_type":"4"}},{"id":1292002,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":77431,"kind":"person","name":"Kling Douglas F","position":1,"cik":"0001699022","reported_name":"Kling Douglas F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Option (right to buy)","published_at":"2025-01-29T22:16:00.000Z","date":"2025-01-28","kind":"exercise","planned":true,"acquired":false,"shares":25385,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The exercise price of the option is 1.16392 euros."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The option was granted on November 22, 2022 to replace an option originally granted on July 6, 2021, which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 121,754 of the shares underlying the option immediately vested on the grant date. 25% of the remaining shares underlying the option vested on March 31, 2022, the one-year anniversary of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date."}],"balance_after":296586,"derivative":{"expiration_date":"2031-07-06","underlying":"Ordinary Shares","underlying_shares":25385},"source":{"system":"sec-edgar","filing":"0000950170-25-010575","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000095017025010575/ownership.xml","form_type":"4"}},{"id":1292001,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":77431,"kind":"person","name":"Kling Douglas F","position":1,"cik":"0001699022","reported_name":"Kling Douglas F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Option (right to buy)","published_at":"2025-01-29T22:16:00.000Z","date":"2025-01-27","kind":"exercise","planned":true,"acquired":false,"shares":104174,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The exercise price of the option is 1.16392 euros."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The option was granted on November 22, 2022 to replace an option originally granted on July 6, 2021, which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 121,754 of the shares underlying the option immediately vested on the grant date. 25% of the remaining shares underlying the option vested on March 31, 2022, the one-year anniversary of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date."}],"balance_after":321971,"derivative":{"expiration_date":"2031-07-06","underlying":"Ordinary Shares","underlying_shares":104174},"source":{"system":"sec-edgar","filing":"0000950170-25-010575","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000095017025010575/ownership.xml","form_type":"4"}},{"id":1292000,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":77431,"kind":"person","name":"Kling Douglas F","position":1,"cik":"0001699022","reported_name":"Kling Douglas F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2025-01-29T22:16:00.000Z","date":"2025-01-28","kind":"sale","planned":true,"acquired":false,"shares":5148,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"These shares were sold in multiple transactions at prices ranging from $21.93 per share to $22.39 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction."}],"balance_after":44000,"source":{"system":"sec-edgar","filing":"0000950170-25-010575","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000095017025010575/ownership.xml","form_type":"4"}},{"id":1291999,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":77431,"kind":"person","name":"Kling Douglas F","position":1,"cik":"0001699022","reported_name":"Kling Douglas F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2025-01-29T22:16:00.000Z","date":"2025-01-28","kind":"sale","planned":true,"acquired":false,"shares":20237,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"These shares were sold in multiple transactions at prices ranging from $20.92 per share to $21.91 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction."}],"balance_after":49148,"source":{"system":"sec-edgar","filing":"0000950170-25-010575","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000095017025010575/ownership.xml","form_type":"4"}},{"id":1291998,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":77431,"kind":"person","name":"Kling Douglas F","position":1,"cik":"0001699022","reported_name":"Kling Douglas F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2025-01-29T22:16:00.000Z","date":"2025-01-28","kind":"exercise","planned":true,"acquired":true,"shares":25385,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The exercise price of the option is 1.16392 euros."}],"balance_after":69385,"source":{"system":"sec-edgar","filing":"0000950170-25-010575","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000095017025010575/ownership.xml","form_type":"4"}},{"id":1291997,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":77431,"kind":"person","name":"Kling Douglas F","position":1,"cik":"0001699022","reported_name":"Kling Douglas F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2025-01-29T22:16:00.000Z","date":"2025-01-27","kind":"sale","planned":true,"acquired":false,"shares":23815,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"These shares were sold in multiple transactions at prices ranging from $23.46 per share to $23.70 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction."}],"balance_after":44000,"source":{"system":"sec-edgar","filing":"0000950170-25-010575","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000095017025010575/ownership.xml","form_type":"4"}},{"id":1291996,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":77431,"kind":"person","name":"Kling Douglas F","position":1,"cik":"0001699022","reported_name":"Kling Douglas F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2025-01-29T22:16:00.000Z","date":"2025-01-27","kind":"sale","planned":true,"acquired":false,"shares":80359,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"These shares were sold in multiple transactions at prices ranging from $22.46 per share to $23.45 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction."}],"balance_after":67815,"source":{"system":"sec-edgar","filing":"0000950170-25-010575","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000095017025010575/ownership.xml","form_type":"4"}},{"id":1291995,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":77431,"kind":"person","name":"Kling Douglas F","position":1,"cik":"0001699022","reported_name":"Kling Douglas F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2025-01-29T22:16:00.000Z","date":"2025-01-27","kind":"exercise","planned":true,"acquired":true,"shares":104174,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The exercise price of the option is 1.16392 euros."}],"balance_after":148174,"source":{"system":"sec-edgar","filing":"0000950170-25-010575","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000095017025010575/ownership.xml","form_type":"4"}},{"id":1308332,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":77431,"kind":"person","name":"Kling Douglas F","position":1,"cik":"0001699022","reported_name":"Kling Douglas F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Ordinary Shares","published_at":"2025-01-07T22:10:29.000Z","date":"2025-01-07","kind":"grant","planned":false,"acquired":true,"shares":44000,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (RSUs), each representing a contingent right to receive one ordinary share. 1/3 of the RSUs will vest on each of the first, second and third anniversaries of the vesting start date, subject to the Reporting Person's continued service through each such date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU was granted on January 7, 2025 for no consideration."}],"balance_after":44000,"source":{"system":"sec-edgar","filing":"0000950170-25-002979","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000095017025002979/ownership.xml","form_type":"4"}},{"id":1311140,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":77431,"kind":"person","name":"Kling Douglas F","position":1,"cik":"0001699022","reported_name":"Kling Douglas F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Option (right to buy)","published_at":"2025-01-06T22:57:08.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying the option will vest on January 2, 2026, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date."}],"balance_after":250000,"derivative":{"exercise_price":25.96,"expiration_date":"2035-01-02","underlying":"Ordinary Shares","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0000950170-25-002374","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000095017025002374/ownership.xml","form_type":"4"}},{"id":1693375,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":77431,"kind":"person","name":"Kling Douglas F","position":1,"cik":"0001699022","reported_name":"Kling Douglas F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Option (right to buy)","published_at":"2024-01-03T22:21:52.000Z","date":"2024-01-01","kind":"grant","planned":false,"acquired":true,"shares":323771,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying the option will vest on January 1, 2025, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date."}],"balance_after":323771,"derivative":{"exercise_price":11.17,"expiration_date":"2034-01-01","underlying":"Ordinary Shares","underlying_shares":323771},"source":{"system":"sec-edgar","filing":"0000950170-24-001141","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1936258/000095017024001141/ownership.xml","form_type":"4"}}]}